Biotech Values

[iwfal]

EXEL -

The failure to stop the trial at the interim analysis almost certainly rules an HR in that range (or better).

Given that EXEL probably used O'Brien Flemming interim analysis (significant majority use OBF) then we know that the HR was >0.75 (the HR they assumed when the designed the powering of the trial).